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1078–5Objectives/Design. Carotid plaque echogenicity quantified by the Gray-Scale Median (GSM) score has been associated
with plaque vulnerability. The aim of this study was to assess whether intensive lipid-lowering treatment with atorvastatin
in patients with carotid artery stenosis ameliorates novel vascular calcification inhibitors, such as osteopontin (OPN) and
osteoprotegerin (OPG), and improves GSM score.
Methods. Ninety-seven patients with carotid stenosis (>40%), but without indication for intervention, were treated for 6
months with atorvastatin (10 mge80 mg) to target LDL< 100 mg/dl. Fifty-two age-and sex-matched healthy individuals
served as the control group. Blood samples and GSM were obtained at the beginning and after 6 months.
Results. Systolic blood pressure, hsCRP, fibrinogen, OPN and OPG levels differed significantly between patients with
carotid stenosis and healthy controls at baseline (p< 0.05). Atorvastatin treatment improved lipid profile and significantly
reduced hsCRP (p¼ 0.002), WBC count (p¼ 0.041), OPN (p< 0.001) and OPG levels (p< 0.001). GSM score
increased considerably after atorvastatin therapy (from 58.33 24.38 to 79.33 22.3; p< 0.001) and that effect appeared
related to OPN (p¼ 0.001), OPG (p¼ 0.013) and LDL (p¼ 0.01) reduction.
Conclusions. In patients with carotid stenosis, intensive lipid-lowering therapy with statins attenuates serum OPN and
OPG levels and enhances carotid plaque echogenicity, outlining their beneficial effects on plaque stability.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid atherosclerosis and stroke remain one of the
leading causes of morbidity and mortality in most
industrialized countries.1 The key factor affecting the
risk of cerebrovascular ischemic events in patients
with carotid atherosclerosis seems to be the composi-
tion of the plaque rather than the degree of luminal
encroachment.2 Plaque prone to rupture, known as
vulnerable plaque, characteristically contains large
areas of lipids and necrosis, abundant macrophages,
less calcified deposits and thin fibrous cap.2
Accumulating interest has focused on understand-
ing how carotid plaque calcification enhances plaquesponding author. N. P. E. Kadoglou, 124 Vosporou Street,
454, Thessaloniki, Greece.
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events.3 Osteopontin (OPN), an acidic phosphopro-
tein, and osteoprotegerin (OPG), a member of the
tumor necrosis factor-a receptor superfamily, have
been recently demonstrated to modulate vascular
calcification.4,5 These bone-matrix proteins inhibit
mineral deposition as well as osteoclastogenesis and
are expressed constitutively by most vascular cells.4
Recent studies have shown an association of serum
OPN and OPG levels with cardiovascular diseases.6,7
The immunodetection of OPN and OPG in human
carotid plaques indicate their contribution to
atherosclerotic process and plaque composition.5,8,9
Nevertheless, their precise role in atherosclerosis
development and their response to pharmaceutical
interventions remain obscure.
Among new imaging methods, ultrasound modali-
ties provide a non-invasive, cheap and easily repeatabler Surgery. Published by Elsevier Ltd. All rights reserved.
662 N. P. E. Kadoglou et al.approach to carotid atherosclerosis. Most recently,
analysis of plaque echogenicity and especially its
quantitative index, Gray Scale Median (GSM) score,
has emerged as an assessment methodology of carotid
plaque vulnerability.10 Echolucent plaques with low
GSM score have been recognized as lipid-rich and
less calcified.11 These unstable plaques correlate with
higher rates of cerebrovascular events.11 Thus increases
of plaque echogenicity could be a valuable marker of
the efficacy of therapeutic strategies on carotid plaque
stability.
The potential usefulness of 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors
(statins), as a part of the conservative treatment of
patients with carotid disease has been cited by the
National Cholesterol Education Project.12 Numerous
trials show that statin agents induce a resounding
and consistent improvement in cardiovascular
end-points, which is mainly attributed to plaque sta-
bilization rather than to plaque regression.12,13 The
beneficial effects of statins are not fully explained by
the baseline or treated LDL cholesterol levels and
may involve non-lipid mechanisms.14 These so-called
‘‘pleiotropic’’ properties include anti-inflammatory,
immunomodulatory, anti-oxidative and direct anti-
atherosclerotic effects resulting in plaque stability.14
Despite the above molecular evidence, practical exam-
inations to determine the modifying effects of statins
on carotid plaque vulnerability are relatively limited.
This study was designed to investigate whether
intensive lipid-lowering therapy with atorvastatin
attenuates serum OPN and OPG levels and increases
GSMvalue in patients with carotid stenosis and indica-
tions for conservative treatment. We also tested the hy-
pothesis that the modification of lipid levels and
vascular calcification inhibitors mediates the atorvas-
tatin-induced effects on the GSM score. The present
study constitutes a part of an ongoing, prospective pro-
ject which aims to identify patients with undiagnosed
carotid stenosis and to apply optimal therapies. The
preliminary baseline data of this project, which derive
from most of our participants, have already been
published.15Materials and Methods
Subjects
This was an open-label, prospective study. Eligibility
for entering this study required recently diagnosed
(within 14 days) stenosis of at least one internal ca-
rotid artery (ICA). The degree of stenosis was >40%,
but there was no indication for revascularization.16Eur J Vasc Endovasc Surg Vol 35, June 2008A group of age- and sex-matched healthy volunteers
without any chronic disease were also enrolled.
Autoimmune diseases, hypothyroidism, osteoporosis,
liver impairment (ALT> 2.5 times higher than the
upper normal limit), renal insufficiency (creatinine
levels> 2.0 mg/dl), coronary artery disease, atrial
fibrillation, malignancy, ongoing or previous use of
bisphosphonates, glucocorticoids, lipid-lowering
medications and contraindications to the use of statins
were exclusion criteria. A total of 155 consecutive
Caucasians subjects, aged 50e75, were initially
included. Among them, 103 patients had newly-
diagnosed ICA stenosis with indications for conserva-
tive treatment, while 52 individuals served as healthy
controls.
After providing written informed consent, eligible
subjects were assigned to the following groups: A)
Symptomatic patients with 40e60% stenosis ICA. B)
Asymptomatic patients with 40e70% stenosis. C)
Healthy subjects. Symptomatic disease was docu-
mented when patients had experienced stroke or TIA
attributed to ipsilateral carotid stenosis. The diagnosis
of ischemic attack was based on the combined evalua-
tion of medical history, neurological examination, and
brain computed tomography (CT) or magnetic
resonance imaging (MRI) examination, when CT
findingswere questionable. On the other hand, asymp-
tomatic patients appeared without focal neurological
symptoms and negative CT and/or MRI scan.Methods
Body weight, height, hip and waist circumference
were measured and body-mass index (BMI) and
waist-to-hip ratio (WHR) calculated.5 Blood pressure
(BP) was measured twice, after keeping participants
in a sitting position for 15 minutes. The mnute
intervals was used for study purposes. All co-
morbidities, medications, smoking habits, and
parental medical history were recorded using
structured questionnaires.
At baseline, all participants underwent an ultra-
sound examination of both carotids. Afterwards,
patients with carotid stenosis (groups A and B) were
treated for 6 months with atorvastatin. The dose was
gradually titrated, at 6 weeks intervals, from 10 mg
to 80 mg to target LDL< 100 mg/dl. The number of
statin pills, already taken by each patient, was
calculated at the end of the study. Compliance was
considered effective if at least 90% of estimated study
medication had been received. Anti-platelet agents
were prescribed to all patients with carotid stenosis
(acetylsalicylic acid 100 mg/day or clopidogrel
663Intensive Lipid-lowering Therapy Ameliorates Novel Calcification Markers and GSM Score75 mg/day). Concomitant pharmaceutical therapy
was modified only when deemed medically appropri-
ate during the research period. Ultrasound examina-
tion was repeated 6 months later only in the
interventional group. The study protocol was
approved by the local ethical committee and
conducted in compliance with the ethical guidelines
of the Declaration of Helsinki.Ultrasound
An ultrasound scanner (General Electric Logiq700,
Riverside, USA) equipped with a 7.5 MHz probe
was used. With the patient in the supine position,
the carotid artery was investigated bilaterally in
a suitable longitudinal and transverse view (the angle
of insonation was less than or equal to 60). The diag-
nosis of carotid stenosis was based on the recommen-
dations of the Society of Radiologists in Ultrasound.17
All images from both carotids were directly recorded
on a personal computer and GSM score was calcu-
lated in longitudinal images using Adobe Photoshop
7.0 software. Image normalization included the
definition of the GSM score of the two reference
points (blood and adventitia) in the original B-mode
image (input values). We then performed the
‘‘curves’’ option of the software so that in the resultant
image, the GSM of blood equals 0 to 5 and that of the
adventitia equals 185 to 195 (output values).18 In this
way, the gray scale values were adjusted according
to the input and the output values of the two reference
points. A single operator who was unaware of the
patient’s history performed all ultrasound examina-
tions and measurements of plaques.
In the symptomatic group, the GSM value of the
culprit lesion, associated with the ipsilateral brain
infarct, was used for study purposes. In case of
more than one unilateral atherosclerotic plaque, the
GSM value of each single plaque was estimated and
the average value was considered for statistical
analysis. In asymptomatic patients with more than
one carotid plaque, we averaged the GSM value of
all plaques in both carotids.Blood analyses
Blood samples were obtained between 8.00 and 9.00
a.m after fasting at the beginning and at the end of
the study. In the symptomatic group, blood samples
were collected at least 14 days after admission to the
hospital for stroke or TIA or at least 7 days after
discharge from the hospital. Fasting plasma glucose
(FPG) and lipid parameters were determined usingstandard enzymatic methods (Olympus AU560, Ham-
burg, Germany). Measurements of HbA1c were done
by high-performance liquid chromatography (Menar-
ini Diagnostics, Florence, Italy). Plasma OPN and
OPG were assayed using quantikine immunoassay
EIA kits (R&D Systems Inc., Minneapolis, USA and
Metra, San Diego, USA). The intra- and inter-assay
coefficients of variance were 2.6% and 5.7% for OPN
and 7% and 6.8% for OPG, respectively. High-sensitiv-
ity C-Reactive Protein (hsCRP) and fibrinogen were
measured by nephelometric assay (Dade Behrin,
BNII, Marburg, Germany) and the Clauss method,
respectively. Samples were frozen and stored
(80 C) until analysis in the same assay.
Statistical analysis
Data are expressed as mean and  SD. Normality of
distribution was assessed by KolmogoroveSmirnov
test. Comparisons of parametric parameters within
and between groups were analyzed by paired-
samples and student’s t-test, respectively. One-way
ANOVA analysis was applied to assess differences
between groups at baseline. Chi-square test was
used for categorical data. The univariate associations
of OPN, OPG, GSM values at baseline and their
changes after treatment were quantified by Pearson
correlation. Changes of GSM, as dependent variable,
and changes of the rest of significant-related parame-
ters, as independent variables, entered a multiple
regression analysis model. All analyses were carried
out by software SPSS-13.0 (SPSS Inc, Chicago, USA).
Two-tailed p value of <0.05 was considered as
statistically significant.
Results
Among 155 participants, full measurements were
obtained in 149 cases. Six patients with carotid steno-
sis were excluded, because they did not have a second
ultrasound measurement (1 died of pneumonia, 5
patients did not return for the second measurement).
Of the remaining 97 individuals with carotid stenosis,
all images were of good quality and therefore, were
included in statistical analysis. Atorvastatin was
well-tolerated and noteworthy adverse effects were
not reported. No patient experienced any cardiovas-
cular event during the study period.
Baseline characteristics
Baseline characteristics of participants are listed in
Tables 1 and 2. Patients with carotid stenosis hadEur J Vasc Endovasc Surg Vol 35, June 2008
Table 1. Clinical and anthropometrical characteristics of patients with carotid atherosclerosis and healthy subjects
Variables Carotid atherosclerosis Healthy control P1 P2
Baseline End
Number 97 52
Male/Female 39/58 20/32 NS e
Age (years) 63.639.92 60.348.83 0.345 e
Smokers (%) 22 (22.68%) 5 (9.62%) NS e
Diabetes (%) 36 (37.11%) e e e
PAD (%) 4 (6.19%) e e e
Anti-HP regimen (%) 63 (64.95%) e e e
BMI (kg/m2) 29.094.47 28.884.55 27.773.62 0.123 0.128
Waist girth (cm) 100.2511.26 99.8511.22 92.8412.39 <0.001 0.192
WHR 0.930.086 0.9240.081 0.9210.089 0.038 0.198
Systolic BP (mmHg) 13120.18 12516.9 12615.05 0.015 <0.001
Diastolic BP (mmHg) 7910.99 7510.08 798.51 0.849 <0.001
GSM 58.3324.38 79.3322.3 e e <0.001
Carotid stenosis (%) 54.636.31 53.986.96 e e 0.823
Data are means  SD. PAD, Peripheral artery disease; Anti-HP regimen, Anti-hypertensive regimen; BMI, Body-mass index; WHR, Waist-
hip ratio; BP, blood pressure; GSM, Gray Scale Median. P1, p values of variables between groups at baseline; P2, p values of changes of
variables within the group of carotid atherosclerosis.
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triglycerides, WBC count, hsCRP, fibrinogen, OPN
and OPG levels compared with healthy individuals
at baseline ( p< 0.05). During the study, 6 patients
with carotid stenosis (3 symptomatic, 3 asymptom-
atic) had their anti-hypertensive regimen modified
(dose titration or new agent addition), while 6 pa-
tients (2 symptomatic, 4 asymptomatic patients)
started taking anti-hypertensive agents to target sys-
tolic/diastolic BP lower than 130/85 mmHg. Treat-
ment modulation resulted in the downregulation of
mean systolic and diastolic BP ( p< 0.001) (Table 3).
Furthermore, we found significant differences
between symptomatic and asymptomatic patients with
carotid stenosis at baseline in OPN (70.18 33.89 ng/
ml vs 55.66 30.59 ng/ml; p¼ 0.040), OPG (8.15
2.46 pmol/L vs 6.97 2.15 pmol/L; p¼ 0.004) and
GSM (48.08 27.35 vs 72 13.08; p< 0.001). Compared
to healthy individuals, OPG levels were significantly
elevated in symptomatic and asymptomatic groupsTable 2. Biochemical characteristics of patients with carotid atherosc
Variables Carotid atherosclerosis
Baseline End
Total cholesterol (mg/dl) 23953 16933
HDL (mg/dl) 4413 4611
LDL (mg/dl) 16132 9427
Triglycerides (mg/dl) 17676 12965
FPG (mg/dl) 12640 12035
*HbA1c (%) 6.621.05 6.380.
hsCRP (mg/L) 4.582.07 1.881.
WBC (cells/mL) 73002119.3 691520
Fibrinogen (mg/dl) 412.4132.27 383.711
Osteopontin (ng/ml) 63.0222.53 43.0817
Osteoprotegerin (pmol/L) 7.542.78 3.791.
Data are means  SD. FPG, Fasting Plasma Glucose; hsCRP, high sens
variables between groups at baseline; P2, p values of changes of varia
* Comparison within groups for HbA1c was performed only in the
Eur J Vasc Endovasc Surg Vol 35, June 2008( p< 0.05), while OPN was considerably increased only
in symptomatic patients (p< 0.001) (Fig. 1).
Effects of atorvastatin treatment
Lipid-lowering therapy elicited marked improvement
in most lipid parameters, hsCRP ( p¼ 0.002), WBC
( p¼ 0.041), OPN ( p< 0.001) and OPG ( p< 0.001)
(Table 2). We must emphasize that no patient with
carotid stenosis had LDL levels <100 mg/dl at base-
line, while 84.76% achieved the target at the end of
the study. Most importantly, atorvastatin treatment
increased GSM considerably (from 58.33 24.38 to
79.33 22.3; p< 0.001), while the degree of carotid lu-
men encroachment remained unaffected ( p¼ 0.823).
The exclusion of patients with modulated anti-hyper-
tensive medications from statistical analysis did not
alter all the aforementioned results (data not shown).
Upon examining symptomatic and asymptomatic
patients, atorvastatin therapy significantly reducedlerosis and healthy subjects
Healthy control P1 P2
.6 23741.2 0.703 <0.001
.5 4712.9 0.168 0.160
.6 16135.8 0.793 <0.001
.6 14066.7 0.029 <0.001
.4 9822.1 <0.001 0.113
96 e e 0.086
09 1.681.93 0.001 0.002
83.1 66701658.5 0.036 0.041
4.72 327.5101.05 <0.001 0.089
.52 38.0113.6 0.002 <0.001
11 3.391.64 <0.001 <0.001
itivity C-Reactive Protein; WBC, White Blood Cells. P1, p values of
bles within the group of carotid atherosclerosis.
diabetic subgroup.
Table 3. Changes of clinical variables in symptomatic and asymptomatic group after intensive lipid-lowering treatment with
atorvastatin
Symptomatic group Asymptomatic group
Baseline Change P1 Baseline Change P1 P2
Number 53 44
Male/Female 21/32 18/26
Smokers (%) 9 (16.98%) 13 (29.55%)
Diabetes (%) 19 (35.85%) 17 (38.63%)
Duration diabetes (yr) 7.175.17 8.384.19
PAD (%) 11 (20.76%) 7 (15.91%)
Anti-HP regimen(%) 37 (69.81%) 26 (59.09%)
Age (years) 64.365.85 62.976.95
BMI (kg/m2) 27.223.54 0.0361.43 0.908 29.994.62 0.2960.97 0.440 0.275
Waist girth (cm) 98.928.80 0.393.19 0.544 100.3311.67 0.732.68 0.038 0.079
WHR 0.9740.064 0.0040.046 0.650 0.9070.087 0.0060.024 0.090 0.512
Systolic BP (mmHg) 13421.6 6.620.2 0.095 13119.7 6.815.9 0.002 0.767
Diastolic BP (mmHg) 799.7 4.110 0.039 8011.7 4.210.5 0.003 0.444
Carotid stenosis (%) 51.274.31 0.370.98 0.912 58.684.12 0.991.46 0.825 0.954
Data are means  SD. Anti-HP regimen, Anti-hypertensive regimen; BMI, body mass index; Systolic BP, systolic blood pressure; Diastolic
BP, diastolic blood pressure; WHR, Waist-hip ratio; GSM, Gray-Scale Median. P1, p values of changes of variables within groups; P2,
p values of changes of variables between groups.
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0.05) and increased GSM in both groups ( p< 0.01)
compared with baseline values. We also noted a signif-
icant reduction of fibrinogen only in asymptomatic
patients. The amount of changes of all variables did
not differ between the symptomatic and asymptom-
atic groups ( p> 0.05) (Table 4, Fig. 1).Correlations
In agreement with our previous study,15 univariate
analysis of carotid atherosclerosis group at baseline
confirmed the inverse association of GSM with
OPN, OPG and waist circumference ( p< 0.01). We
next examined the changes of GSM, OPN and OPG
in relation to the changes of cardiovascular risk
factors after atorvastatin administration. The atorvas-
tatin-induced augmentation of GSM was significantly
correlated with the changes of OPN (r¼0.414, p¼
0.001), OPG (r¼0.584, p¼ 0.013) and LDL (r¼
0.472, p¼ 0.01). Besides this, changes of OPN
related to OPG alterations (r¼ 0.538, p¼ 0.028).
Standard multiple regression analysis revealed that
the atorvastatin-related changes of OPN, OPG, and
LDL constituted independent predictors of GSM
changes ( p¼ 0.008) and seemed to explain 52.3% of
its variation.Discussion
The present study demonstrated serum OPN and
OPG levels to be increased in patients with carotid
stenosis and independently associated with carotid
plaque echogenicity and symptomatology. Thesebone-matrix proteins are now the focus of increasing
research in cardiovascular diseases, but their modula-
tion by statins has not yet been explored. In our study,
intensive atorvastatin therapy downregulated the
levels of both biochemical markers and considerably
increased GSM score without regression of plaque
size in patients with carotid stenosis. That effect was
related to the reduction in OPN, OPG and LDL levels
implicating a novel angio-protective mechanism by
which statins may enhance carotid plaque stability.
There has been increasing awareness surrounding
the association of OPN and OPG with carotid disease.
We and other investigators have previously demon-
strated increased serum OPN and OPG levels in
patients with carotid atherosclerosis.15,19,20 Our results
confirmed these studies, while most elevated levels of
serum OPN and OPG levels were found in stroke and
TIAs survivors group indicating the association of
bone-remodeling proteins with symptomatology.
This notion is further supported by the independent
association of serum OPN and OPG with GSM values.
Up to now, there has been limited evidence
concerning the effects of statins on OPN. In vitro stud-
ies from cultured rat aortic smooth muscle cells
(SMCs) or aorta tissue obtained from hypothyroid
mice have shown statins to dose-dependently reduce
OPN expression.21,22 Preliminary data from Tanaka
et al. demonstrated that 6 months treatment with ator-
vastatin (20 mg) reduced plasma OPN levels by 19%
in a small sample of hypercholesterolemic patients.23
In our study the hypolipidemic regimen elicited 32%
reduction in OPN levels. A plausible explanation for
that marked effect derives from the interplay between
lipid-lowering and cardiovascular OPN expression.24

























































Fig. 1. Serum levels of osteopontin and osteprotegerin and
GSM values at baseline and at the end of the study. Data
are mean  SD. jjp<0.05 difference of variables at baseline
between A and B groups; *p<0.05 difference of variables
at baseline between A and C groups; **p<0.05 difference
of variables at baseline between B and C groups; #p<0.05
changes of variables within groups. A, symptomatic group;
B, asymptomatic group; C, healthy control group.
666 N. P. E. Kadoglou et al.because atorvastatin reduced serum OPN indepen-
dently of lipid parameters changes. Alternatively we
postulated the atorvastatin-induced modulation of
OPN expression via non-lipid mechanisms such as
mevalonate pathways and isoprenylated mole-
cules.21,22 Taking into consideration that OPN consti-
tutes a novel cardiovascular risk factor the above
beneficial effects of atorvastatin are quite promising,
but remain to be proved by longitudinal studies.
In the light of the ‘‘pleiotropic’’ properties of statins,
a recent study showed that atorvastatin treatment of
human osteoblasts stimulated dose-dependently theEur J Vasc Endovasc Surg Vol 35, June 2008production of OPG.25 In contrast, treatment with
atorvastatin suppressed, in a dose-dependent manner,
the production of OPG from endothelial and vascular
SMCs.26 Perhaps the different cell-type may explain
the above discrepancy. In our study we documented
for first time the suppression of serum OPG levels by
intensive statin therapy. Concerning that OPG is
strongly related to cardiovascular diseases, our finding
is of clinical relevance. Future studies will address the
question of whether statin-induced reduction of OPG
is another vasculoprotective mechanism or a sensitive
bystander of atherosclerotic process.
To our knowledge this is the first study using GSM
values to quantify the effects of lipid-lowering ther-
apy on carotid plaque composition. We documented
that intensive atorvastatin therapy did not limit
carotid narrowing, but significantly increased carotid
plaque echogenicity. It is well-established that statin
administration curtails carotid plaque progression,
reduces cerebrovascular events rate and decreases
perioperative morbidity and mortality in patients
undergoing carotid surgical or endovascular revascu-
larization.27 Stabilization of lesions by modification of
structure and content, rather than simple improve-
ment in the luminal diameter explains the above
mechanistic effects and provides a new therapeutic
target in carotid disease, whose mainstay of therapy
remains surgical. Moreover the present study
underscores that ultrasound image analysis is a practi-
cal index to monitor plaque texture changes during
the surveillance period.
Although the extent to which statins influence
plaque biology in vivo has engendered controversy,
several potential mechanisms account for the
augmentation of plaque echodensity. Statins predom-
inantly reduce plasma concentration of LDL, a well-
established cardiovascular risk factor. A recent meta-
analysis of all randomized trials testing statin drugs
found a 21% risk reduction for stroke, closely associ-
ated with reductions in LDL levels.28 Next to the
lipid-lowering effects, statin treatment has potential
‘‘pleiotropic’’ anti-atherosclerotic effects.14 In our
study atorvastatin administration improved lipid
profile and decreased inflammatory burden. Mean-
while the increment of GSM value was significantly
correlated with the reduction of OPN, OPG and
LDL levels. These results were supported by
multivariate regression analysis, after adjustment for
potential confounders. Taken all together we postu-
lated that the enhancement of carotid plaque
echogenicity was attributed to the ‘‘pleiotropic’’ func-
tions of statins besides to lipid-lowering.
Extensive research suggests that subintimal lipid
deposition, lipid oxidation and inflammatory cells
Table 4. Changes of biochemical variables in symptomatic and asymptomatic group after intensive lipid-lowering treatment with
atorvastatin
Symptomatic group Asymptomatic group
Baseline Change P1 Baseline Change P1 P2
Total cholesterol (mg/dl) 22450.1 59.336.48 <0.001 24953.4 84.649.19 <0.001 0.522
HDL (mg/dl) 388 6.112.67 0.056 4814.1 0.14.33 0.969 0.263
LDL (mg/dl) 14820.9 54.116.27 <0.001 16934.6 76.923.29 <0.001 0.535
Triglycerides (mg/dl) 19578.4 55.341.12 0.004 16573.4 42.339.08 0.001 0.805
FPG (mg/dl) 12635.2 8.630.79 0.541 12642.3 3.033.88 0.503 0.346
*HbA1c (%) 6.880.99 0.21.04 0.136 6.311.10 0.280.56 0.097 0.637
hsCRP (mg/L) 4.287.16 2.247.72 0.015 4.795.41 3.035.23 0.021 0.663
WBC (cells/mL) 75332118.1 664.81836.13 0.024 6795276.1 213.81015.22 0.813 0.811
Fibrinogen (mg/dl) 419.36125.24 15.62118.35 0.415 397.89151.45 72.08122.04 0.019 0.481
Data are means  SD. FPG, Fasting plasma glucose; hsCRP, high sensitivity C-Reactive Protein; WBC, White Blood Cells. P1, p values of
changes of variables within groups; P2, p values of changes of variables between groups.
* Comparison within and between groups for HbA1c was performed only in diabetic patients.
667Intensive Lipid-lowering Therapy Ameliorates Novel Calcification Markers and GSM Scoreinfiltration constitute the substrate of atherosclerotic
calcification.4 Despite the counter-regulatory effects
of statins on the above pathways, their role in athero-
sclerotic calcification is still controversial. Recent stud-
ies suggest that statins prevent calcification of
atherosclerotic plaques in hyperlipidemic animals or
cultures of human VSMCs.29,30 On the other hand sta-
tins were found to enhance bone formation in carotid
plaques.31 In our study the atorvastatin-induced in-
crease of GSM was independently associated with
the reduction of vascular calcification inhibitors. Re-
garding that elastin and calcium content determine
predominantly carotid plaque echogenicity, our re-
sults support the second hypothesis of statins contri-
bution to atherosclerotic calcification.32 However we
could not examined carotid specimens and thus our
preliminary data require further investigation.
Our selected population could induce a bias.Most of
our patients were characterized by low compliance
with their physicians’ recommendations. Patients
with these characteristics would be expected to have
more advanced atherosclerosis with multiple simulta-
neous comorbidities. Perhaps statin administration to
patients with different characteristics might have
conferred less pronounced results. We must also
comment the relative weakness of GSM to measure
the morphology only in the longitudinal dimension.
Future development of GSM measurements in three
dimensions will provide the possibility of examining
the entire lesion. Another limitation is that we cannot
infer firm conclusion about the effects of statin on
cardiovascular outcomes due to the short duration
of our study. Besides this a small proportion of our
patients had its concomitant drug treatment modified,
which might have influenced our results. However
after adjustment for these patients, we found negligible
influence. Finally we confined our selection criteria
to patients with moderate-to-high degree of carotidstenosis under conservative treatment. It would be
valuable to study the effects of statins on plaque echo-
genicity across the whole range of carotid stenosis.
In conclusion, we demonstrated that atorvastatin
treatment improved lipid profile, suppressed serum
OPN and OPG levels and increased carotid plaque
echogenicity in patients with moderated carotid steno-
sis. Most importantly the latter effects seemed to medi-
ate the statin-induced stabilization of atherosclerotic
plaque. Overall our study provide preliminary
evidence that other criteria than the degree of carotid
stenosis and lipid levels should be set for statin therapy
initiation in patients with carotid atherosclerosis.Acknowledgements
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